Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone

Archive ouverte

Touret, Franck | Gilles, Magali | Klitting, Raphaelle | Aubry, Fabien | de Lamballerie, Xavier | Nougairède, Antoine

Edité par CCSD -

International audience. Zika virus (ZIKV) has recently become dispersed throughout the tropics and sub-tropics, causing epidemics associated with congenital disease and neurological complications. There is currently no commercial vaccine for ZIKV. In this study, we describe the initial development of a chimeric virus containing the prM/E proteins of a ZIKV epidemic strain incorporated into a yellow fever 17-D attenuated backbone. Using the versatile and rapid ISA (Infectious Subgenomic Amplicons) reverse genetics method, we compared different constructs and confirmed the need to modify the cleavage site between the pre-peptide and prM protein. Genotypic characterization of the chimeras indicated that the emergence of compensatory mutations in the E protein was required to restore viral replicative fitness. Using an immunocompromised mouse model, we demonstrated that mice infected with the chimeric virus produced levels of neutralizing antibodies that were close to those observed following infection with ZIKV. Furthermore, pre-immunized mice were protected against viscerotropic and neuroinvasive disease following challenge with a heterologous ZIKV strain. These data provide a sound basis for the future development of this ZIKV vaccine candidate.

Suggestions

Du même auteur

Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages

Archive ouverte | Driouich, Jean-Sélim | CCSD

International audience. Therapeutic monoclonal antibodies have been successful in protecting vulnerable populations against SARS-CoV-2. However, their effectiveness has been hampered by the emergence of new variants...

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2

Archive ouverte | Driouich, Jean-Sélim | CCSD

International audience. BACKGROUND : To address the emergence of SARS-CoV-2, multiple clinical trials in humans were rapidly started, including those involving an oral treatment by nitazoxanide, despite no or limite...

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Archive ouverte | Touret, Franck | CCSD

International audience. A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there...

Chargement des enrichissements...